Indivior (LON:INDV) Receives “Buy” Rating from Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of Indivior (LON:INDV) in a research report released on Tuesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has a GBX 1,800 ($22.88) target price on the specialty pharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,500 ($19.07) price objective on shares of Indivior in a report on Thursday, September 5th.

Indivior Price Performance

Shares of LON:INDV opened at GBX 931 ($11.84) on Tuesday. Indivior has a 1-year low of GBX 554.50 ($7.05) and a 1-year high of GBX 1,770 ($22.50). The company has a current ratio of 0.85, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00. The stock has a market cap of £1.20 billion, a PE ratio of -1,155.41, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The stock’s fifty day simple moving average is GBX 768.84 and its two-hundred day simple moving average is GBX 923.78.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.